Last reviewed · How we verify

IBU TID — Competitive Intelligence Brief

IBU TID (IBU TID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Inflammation.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Pain Management, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

IBU TID (IBU TID) — Pfizer. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IBU TID TARGET IBU TID Pfizer phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2
optimized ibuprofen optimized ibuprofen OSF Healthcare System marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2
Ibuprofen, Hydrocortisone Ibuprofen, Hydrocortisone X-pert Med GmbH marketed NSAID + corticosteroid combination COX-1, COX-2, glucocorticoid receptor
Non- effervescent Paracetamol kern Non- effervescent Paracetamol kern Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina marketed Analgesic and antipyretic Cyclooxygenase (COX-1, COX-2)
Pranoprofen eye drops Pranoprofen eye drops Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2)
Standard Dose Ibuprofen Standard Dose Ibuprofen Ottawa Hospital Research Institute marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2
Codeine paracetamol Codeine paracetamol Napp Pharmaceuticals Limited marketed Opioid analgesic combination Opioid receptors (μ, δ, κ); cyclooxygenase (COX-1, COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

  1. Università degli Studi di Brescia · 4 drugs in this class
  2. Bausch & Lomb Incorporated · 4 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Pfizer · 3 drugs in this class
  5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
  6. Organon and Co · 3 drugs in this class
  7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
  8. Bezmialem Vakif University · 2 drugs in this class
  9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
  10. Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IBU TID — Competitive Intelligence Brief. https://druglandscape.com/ci/ibu-tid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: